Bharat Biotech launches cell cultured H1N1 vaccine in India
This article was originally published in Scrip
Bharat Biotech of India has launched an indigenously developed cell cultured H1N1 swine flu vaccine on the domestic market.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.